3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Neoplasms
1
Interventions
pembrolizumab
28
Docetaxel
21
Gemcitabine
19
Nivolumab
14
Paclitaxel
13
Prednisone
11
Leuprolide
11
pazopanib
10
Radiotherapy
10
Cisplatin
10
Sunitinib
9
Sorafenib
9
Ipilimumab
8
Blood Specimen Collection
8
Bevacizumab
8
avelumab
7
Therapeutics
7
Thalidomide
7
Cyclophosphamide
7
Carboplatin
7
atezolizumab
6
Standard of Care
6
Radiation
6
Mitomycin
6
Interleukin-2
6
Cetuximab
6
Axitinib
6
padeliporfin
5
cemiplimab
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
AM0010
×
Genitourinary
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled